Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»318710.69541/NRIPH.2026.02.014Научная статьяInternet survey — a new way to study the tolerability of antidepressantsDrobizhevMikhail Yuryevichdmyu2001@mail.ruPolskayaElena Alexandrovnapolskaya@neurology.ruN. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russian FederationFederal State Budgetary Scientific Institution «Scientific Center of Neurology», Moscow, Russian Federation260620262858927062026Copyright © 2026,2026A survey of viewers of the @psyhfarm-tv YouTube channel (108,000 subscribers) revealed that the mechanism of action (serotonin reuptake inhibition, serotonin and norepinephrine reuptake inhibition, receptor antagonism and/or agonism) of 17 antidepressants influences patient assessments of their tolerability. This assessment worsens with the number of neurons (especially histamine and acetylcholine) affected by the antidepressant, as well as the number of mechanisms of action.Internet, survey, tolerability, antidepressants, mechanism of action.Интернет, опрос, переносимость, антидепрессанты, механизм действия.1.Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357—1366. DOI: 10.1016/S0140-6736(17)32802—72.Al Nakhebi O, Albu-Kalinovic R, Bosun A, Neda-Stepan O, Gliga M, et al. Management of Systemic Cardiotoxicity Associated with Antidepressant Use in Patients with Depressive Disorders: A Systematic Review J Clin Med. 2025;14(11):3696. DOI: 10.3390/jcm141136963.Yumeng Li, Xiaoyu Du, Huizhen Wu The risk of hyponatremia induced by SSRIs and SNRIs antidepressants: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2025;26(1):144.2025;26(1):144. DOI: 10.1186/s40360-025-00977-14.IsHak W. W., Drew H, Renteria S, Totlani J, Murphy N, et al. Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications. BMC Psychiatry. 2025;25(1):939. DOI: 10.1186/s12888-025-07141-35.Shahid S, Iqbal M, Bhatti U, Ali S. I., Farooq A, Comparative efficacy and safety of tricyclic antidepressants vs. serotonin-norepinephrine reuptake inhibitors for migraine prophylaxis: A systematic review and meta-analysis Clin Neurol Neurosurg. 2025;258:109—149. DOI: 10.1016/j.clineuro.2025.1091496.Heesche M. I., Videbech P. [The impact of psychotropic drugs on driving performance] [Article in Danish] Ugeskr Laeger. 2025;187(33):V07240479. DOI: 10.61409/V072404797.Стал С. М. Основы психофармакологии. Теория и практика. Москва: ГЭОТАР-Медиа; 2022.8.Kokkali M, Pinioti E, Lappas A. S., Christodoulou N, Samara M. Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis. CNS Drugs. 2024;38(10):753—769. DOI: 10.1007/s40263-024-01110-29.Fornaro M., Caiazza C., Rossano F., Cilmi F., Prisco M. De, et al. Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials: NMA driving and hypnotics Eur Neuropsychopharmacol. 2024;81:53—63. DOI: 10.1016/j.euroneuro.2024.01.011